Monaco Asset Management SAM Purchases 576,022 Shares of Nkarta, Inc. $NKTX

Monaco Asset Management SAM lifted its position in shares of Nkarta, Inc. (NASDAQ:NKTX) by 29.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,546,932 shares of the company’s stock after acquiring an additional 576,022 shares during the quarter. Nkarta makes up 0.8% of Monaco Asset Management SAM’s investment portfolio, making the stock its 26th largest position. Monaco Asset Management SAM owned approximately 3.59% of Nkarta worth $4,712,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Geode Capital Management LLC grew its stake in shares of Nkarta by 0.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,208,378 shares of the company’s stock worth $2,006,000 after acquiring an additional 10,065 shares during the period. Millennium Management LLC bought a new position in shares of Nkarta during the 3rd quarter worth $1,549,000. Goldman Sachs Group Inc. grew its stake in shares of Nkarta by 13.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 681,068 shares of the company’s stock worth $1,253,000 after acquiring an additional 80,211 shares during the period. Peapod Lane Capital LLC grew its stake in shares of Nkarta by 0.7% during the 4th quarter. Peapod Lane Capital LLC now owns 676,199 shares of the company’s stock worth $1,251,000 after acquiring an additional 4,933 shares during the period. Finally, AQR Capital Management LLC grew its stake in shares of Nkarta by 300.5% during the 1st quarter. AQR Capital Management LLC now owns 672,078 shares of the company’s stock worth $1,237,000 after acquiring an additional 504,272 shares during the period. Institutional investors own 80.54% of the company’s stock.

Wall Street Analyst Weigh In

NKTX has been the subject of several research reports. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Nkarta in a research note on Wednesday, May 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nkarta in a research note on Friday, March 27th. Mizuho cut their price target on Nkarta from $14.00 to $12.00 and set an “outperform” rating for the company in a research note on Tuesday, March 31st. Wall Street Zen downgraded Nkarta from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Finally, Evercore set a $9.00 price objective on Nkarta in a report on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.75.

Nkarta Stock Performance

Shares of NKTX opened at $3.25 on Monday. The stock’s 50-day simple moving average is $2.70 and its 200 day simple moving average is $2.30. The stock has a market capitalization of $232.51 million, a price-to-earnings ratio of -2.43 and a beta of 0.91. Nkarta, Inc. has a 52-week low of $1.63 and a 52-week high of $3.65.

Nkarta (NASDAQ:NKTX) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.02. On average, research analysts forecast that Nkarta, Inc. will post -1.5 earnings per share for the current fiscal year.

Nkarta Company Profile

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.